Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Nichi-Iko’s Shipment Halt for 9 APIs Was Due to Biz Suspension
March 5, 2021
- Takeda Takes Back Rare Epilepsy Drug in Revised Deal with Ovid
March 5, 2021
- JCR to Build New Manufacturing Facility for COVID-19 Vaccine
March 5, 2021
- Alesion Top-Selling Drug in February: Encise
March 5, 2021
- Mitsubishi Tanabe Aims for Growth with Global Hopefuls in Pipeline: New Biz Plan
March 5, 2021
- J-TEC Now Consolidated Subsidiary of Teijin
March 4, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Mitsubishi Tanabe to Launch US Research Center for CNS Drug Discovery
March 4, 2021
- AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
- Eisai’s Sleep Inducer Dayvigo Approved in Hong Kong
March 3, 2021
- MSD Files Refractory Cough Medicine in Japan
March 3, 2021
- Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
- Mitsubishi Tanabe Licenses Therapeutic App for Depression to DT Axis
March 3, 2021
- Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
- Comirnaty Label Updated in Japan to Ease Storage Temperature: Pfizer/BioNTech
March 2, 2021
- Ono, PeptiDream Ink License Pact for Peptide Drug Discovery
March 2, 2021
- Kissei Seeks Approval for C5aR Inhibitor Avacopan in Japan
March 2, 2021
- Idorsia Files Japan NDA for Clazosentan
March 2, 2021
- Online Meeting Promotions Rise on Decrease in Face-to-Face Visits, In-Hospital Seminars in December: Intage
March 2, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…